Enliven therapeutics announces closing of public offering of common stock and pre-funded warrants and full exercise of the underwriters' option to purchase additional shares

Boulder, colo. , june 16, 2025 /prnewswire/ -- enliven therapeutics, inc. (enliven or the company) (nasdaq: elvn), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its underwritten public offering of 9,920,987 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,526,250 additional shares of its common stock, at a price to the public of $19.66 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,780,263 shares of its common stock at a price to the public of $19.659 per pre-funded warrant, which represents the per share public offering price of each share of enliven's common stock less the $0.001 per share exercise price for each pre-funded warrant.
ELVN Ratings Summary
ELVN Quant Ranking